Generation of a homozygous RANGRF knockout hiPSC line by CRISPR/Cas9 system

Meiling Jiang1, Chengcheng Tang1, Xian Luo1

  • 1Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, South China Institute of Large Animal Models for Biomedicine, School of Biotechnology and Health Science, Wuyi University, Jiangmen, China.

Stem Cell Research
|June 16, 2023
PubMed

Insights

Researchers created a RAN Guanine Nucleotide Release Factor (RANGRF) knockout cell line. This new model aids in studying cardiomyopathy and testing gene therapies for heart conditions.

Area of Science:

  • Cardiovascular Biology
  • Molecular Genetics
  • Cell Biology

Background:

  • The RAN Guanine Nucleotide Release Factor (RANGRF) gene encodes the MOG1 protein, crucial for Nav1.5 transport.
  • Nav1.5 channel dysfunction due to mutations is associated with cardiac arrhythmias and cardiomyopathy.
  • Understanding RANGRF's role is vital for cardiac disease research.

Purpose of the Study:

  • To investigate the function of RANGRF in the context of cardiac health.
  • To generate a cellular model for studying RANGRF-related cardiac pathologies.
  • To create a tool for evaluating potential gene therapies for cardiomyopathy.

Main Methods:

  • CRISPR/Cas9 gene editing technology was employed.
  • A homozygous RANGRF knockout human induced pluripotent stem cell (hiPSC) line was generated.
  • The resulting cell line serves as a disease model.

Main Results:

  • A functional RANGRF knockout hiPSC line was successfully established.
  • This cell line provides a platform for mechanistic studies.
  • The model is suitable for screening gene therapy candidates.

Conclusions:

  • The RANGRF knockout hiPSC line is a significant resource for cardiac research.
  • This model will advance the understanding of cardiomyopathy.
  • It facilitates the development and testing of novel therapeutic strategies for heart disease.